Indivior Doses First Subject In Phase 2 Study Of INDV-2000 For Opioid Use Disorder, Assessing Safety And Efficacy Over 3 Months In Treatment-Seeking Individuals
Indivior Doses First Subject In Phase 2 Study Of INDV-2000 For Opioid Use Disorder, Assessing Safety And Efficacy Over 3 Months In Treatment-Seeking Individuals
Indivior對INDV-2000用於防治濫用阿片類藥物障礙的2期研究的首個受試者實施給藥，評估用於尋求治療的個體中3個月的安全性和有效性。
- Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid Use Disorder.
- INDV-2000 is an investigational non-opioid treatment that acts through the orexin pathway, shown to play a key role in the neurobiology of substance use disorder in animals.
- Recent animal studies have demonstrated that selective Orexin-1 receptor antagonism can reduce self-administration of opioids and synthetic opioids such as fentanyl and remifentanil
- 雙盲安慰劑對照研究旨在測量INDV-2000在中度至重度阿片類物質使用障礙患者中的安全性和療效，研究歷時3個月。
- INDV-2000是一種正在調查中的非阿片類治療藥物，通過促進睡眠激素通路起作用，並在動物物質使用障礙的神經生物學中發揮關鍵作用。
- 最近的動物研究表明，選擇性的Orexin-1受體拮抗劑可以減少阿片類物質和合成阿片類物質（如芬太尼和雷米芬太尼）的自我服用。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。